Patents by Inventor Kenneth L. Hensley

Kenneth L. Hensley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040034093
    Abstract: The present invention provides methods for enhancing muscle performance and/or endurance by administering a composition comprising a desmethyl tocopherol. Athletic performance and sports medicine in general are benefited by the methods of the invention. In addition, the invention provides therapeutic utility to muscle disorders that involve nitrative stress and/or inflammation.
    Type: Application
    Filed: May 14, 2003
    Publication date: February 19, 2004
    Inventors: Kenneth L. Hensley, Robert A. Floyd
  • Patent number: 6569902
    Abstract: PBN (&agr;-phenyl-tert-butylnitrone), and its derivatives nitrone-based free radical traps, significantly reduce preneoplastic nodule development as well as inhibit hepatocellular carcinoma (HCC) formation at very low levels. The involvement of reactive oxygen species (ROS) in cancer development has been strongly implicated for many years. The involvement of ROS has been strongly implicated in cancer development is a model system where feeding a choline deficiency (CD) diet to rats leads to hepatocellular carcinoma (HCC) development. Administering PBN in the drinking water inhibits HCC formation. Preneoplastic nodule growth in the liver is significantly suppressed by administering PBN, or some of its natural metabolites, in the diet. The effectiveness of PBN in preventing HCC development in the CD liver model is considered due to its prevention of tumor development after the target cells have already been initiated, i.e. genetically changed into tumor cells.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: May 27, 2003
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Robert A. Floyd, Yashige Kotake, Kenneth L. Hensley, Dai Nakae
  • Patent number: 6346544
    Abstract: The present invention involves the use of desmethyl tocopherols such as gamma tocopherol for the protection of cardiovascular tissue from nitrative stress. While mechanisms other than scavenging of reactive nitrogen species may be involved, desmethyl tocopherols exhibit significant protection and may be utilized to treat or help prevent cardiovascular particularly arterial vascular disease. The desmethyl tocopherols may be administered dietarily or parenterally when a more direct dosage is desired. Both routes may be utilized together or separately to optimize therapeutic and prophylactic benefits. The lessening of damage induced by reactive nitrogen species leads to the lessening of arterial blockage in thrombosis.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: February 12, 2002
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Kenneth L. Hensley, Robert A. Floyd
  • Publication number: 20020006954
    Abstract: The present invention involves the use of desmethyl tocopherols such as gamma tocopherol for the prevention of and treatment of neurological disorders. Dietary or parenteral administration of desmethyl tocopherols inhibits the undesired nitration of neurological components.
    Type: Application
    Filed: February 27, 2001
    Publication date: January 17, 2002
    Applicant: Oklahoma Medical Research Foundation
    Inventors: Kenneth L. Hensley, Robert A. Floyd
  • Publication number: 20020004531
    Abstract: PBN (&agr;-phenyl-tert-butylnitrone), and its derivatives nitrone-based free radical traps, significantly reduce preneoplastic nodule development as well as inhibit hepatocellular carcinoma (HCC) formation at very low levels. The involvement of reactive oxygen species (ROS) in cancer development has been strongly implicated for many years. The involvement of ROS has been strongly implicated in cancer development is a model system where feeding a choline deficiency (CD) diet to rats leads to hepatocellular carcinoma (HCC) development. Administering PBN in the drinking water inhibits HCC formation. Preneoplastic nodule growth in the liver is significantly suppressed by administering PBN, or some ofits natural metabolites, in the diet. The effectiveness of PBN in preventing HCC development in the CD liver model is considered due to its prevention of tumor development after the target cells have already been initiated, i.e.genetically changed into tumor cells.
    Type: Application
    Filed: March 28, 2001
    Publication date: January 10, 2002
    Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Robert A. Floyd, Yashige Kotake, Kenneth L. Hensley, Dai Nakae
  • Publication number: 20010044462
    Abstract: The present invention involves the use of desmethyl tocopherols such as gamma tocopherol for the protection of cardiovascular tissue from nitrative stress. While mechanisms other than scavenging of reactive nitrogen species may be involved, desmethyl tocopherols exhibit significant protection and may be utilized to treat or help prevent cardiovascular particularly arterial vascular disease. The desmethyl tocopherols may be administered dietarily or parenterally when a more direct dosage is desired. Both routes may be utilized together or separately to optimize therapeutic and prophylactic benefits. The lessening of damage induced by reactive nitrogen species leads to the lessening of arterial blockage in thrombosis.
    Type: Application
    Filed: February 27, 2001
    Publication date: November 22, 2001
    Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION.
    Inventors: Kenneth L. Hensley, Robert A. Floyd